1. France Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Vetoquinol SA

Vetoquinol SA

79.70
EUR
+1.50
(+1.92%)
837.64MMarket Cap
Mar 25Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
25.31
26.58
28.88
29.55
29.7
31.07
33.47
36.15
44.07
45.62
44.73
45.71
45.23
- -
Basic EPS, GAAP
1.99
2.17
2.04
2.35
2.94
3.06
2.42
1.63
5.31
4.06
4.7
4.98
4.94
- -
Free Cash Flow per Basic Share
1.74
2.54
2.14
2.5
2.32
2
3.19
-4.5
3.27
3.41
5.95
5.78
4.42
- -
Dividend per Share
0.35
0.37
0.39
0.41
0.43
0.46
0.48
0.38
0.5
0.8
0.8
0.85
0.9
- -
Book Value per Share
19.94
22.62
24.4
26.69
28.31
30.66
32.65
31.43
37.3
40.95
44.54
48.8
50.87
51.52
Tangible Book Value per Share
12.2
12.19
13.89
16.13
18.32
20.22
18.08
9.88
15.16
20.25
25.18
30.28
33.62
34.88
Basic Weighted Avg Shares
12
12
12
12
12
12
12
12
12
12
12
12
12
12
Sales/Revenue/Turnover
300
315
343
350
352
368
396
427
521
540
529
539
526
- -
Operating Margin (%)
11.3
11.25
11.62
12.02
12.98
13.14
11.63
13.19
16.47
15.61
14.69
14.15
14.97
- -
Depreciation Expense
12
13
18
16
12
12
24
46
5
42
35
31
34
- -
Net Income, GAAP
24
26
24
28
35
36
29
19
63
48
56
59
57
- -
Effective Tax Rate (%)
26.8
31.56
33.73
29.73
19.31
25.05
30.64
46.76
27.48
34.02
27.75
27.57
28.57
- -
Profit Margin (%)
7.87
8.17
7.05
7.94
9.89
9.85
7.22
4.5
12.06
8.89
10.5
10.88
10.91
- -
Working Capital
115
138
149
165
173
190
165
68
117
168
224
280
309
330
LT Debt
11
38
24
15
7
- -
7
8
7
10
10
11
8
7
Total Equity
236
268
289
316
336
363
386
372
441
485
527
576
591
609
Return on Invested Capital (%)
8.16
7.28
6.48
7.81
9.83
9.3
6.87
4.1
12.03
9.33
9.53
9.16
8.67
- -
Return on Capital (%)
8.7
8.74
7.59
8.48
10.15
10.11
7.6
4.39
13.28
10.15
10.74
10.42
9.68
- -
Return on Common Equity (%)
10.17
10.22
8.66
9.19
10.68
10.38
7.63
5.07
15.46
10.37
10.98
10.64
9.83
- -

Capital Structure

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
5
7
6
LT Borrowings
- -
- -
- -
LT Finance Leases
9
8
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
877
971
838

Working Capital

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
416
458
471
Cash, Cash Equivalents & STI
182
221
235
Accounts Receivable, Net
89
89
90
Inventories
131
122
133
Total Current Liabilities
134
149
140
Payables & Accruals
- -
- -
- -
ST Debt
5
7
6
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.54%
9.84%
2.69%
Free Cash Flow
-30.83%
-24.4%
-24.65%
Net Income, GAAP
21.31%
44.5%
-2.26%
Sales/Revenue/Turnover
4.57%
4.58%
-2.51%
Total Cash Common Dividend
- -
- -
3.42%

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
539
2025
- -
- -
526
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
4.98
2025
- -
- -
4.94
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.85
2025
- -
- -
0.9
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Matthieu Jean Frechin
Full Time Employees
2,501
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Magny-Vernois Lure BF France 70204
IPO Date
Nov 17, 2006
Website
vetoquinol.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Vetoquinol S.A. operates as a global animal health enterprise, engaging in the research, development, production, and distribution of veterinary medications and non-medicinal offerings across Europe, the Americas, Africa, the Middle East, Asia, and Oceania. The company’s extensive product line addresses critical areas such as pain, mobility, and inflammation management; dermatology, hygiene, and overall care; parasitic infections; udder health; various infectious diseases; reproductive health; behavior modification; internal medicine; and cardiology-nephrology solutions. These diverse products are tailored for a wide array of animal species, including companion animals like dogs and cats, as well as livestock such as cattle, pigs, and poultry. Established in 1933 and based in Lure, France, Vetoquinol, a subsidiary of Soparfin SCA, maintains a strategic focus on innovation and its high-growth "Essentials" product portfolio, which continues to drive its performance, with annual sales reaching €539 million in 2024.